12:00 AM
 | 
Aug 16, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Intranasal fluticasone propionate: Phase II data

A post hoc subgroup analysis of a double-blind Phase II trial in 109 patients showed that twice-daily intranasal fluticasone significantly reduced polyp size in patients with baseline summed polyp scores of 2, 3 and 4 at weeks 8 and 12 vs. placebo (p<0.033 for all), but not at week 4. Larger polyps result in a higher summed polyp score on the...

Read the full 285 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >